{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:16Z","timestamp":1790286916764,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":792,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1111\/bjd.12279","type":"journal-article","created":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T16:21:44Z","timestamp":1361204504000},"page":"172-176","source":"Crossref","is-referenced-by-count":23,"title":["Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases"],"prefix":"10.1093","volume":"169","author":[{"given":"J.S.","family":"Green","sequence":"first","affiliation":[{"name":"Department of Dermatology; University of Colorado Denver; Anschutz Medical Campus, 1665 Aurora Court, Mail Stop F703 Aurora CO 80011 U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Norris","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University of Colorado Denver; Anschutz Medical Campus, 1665 Aurora Court, Mail Stop F703 Aurora CO 80011 U.S.A"},{"name":"Denver Veterans Affairs Medical Center; Denver CO 80220 U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wisell","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University of Colorado Denver; Anschutz Medical Campus, 1665 Aurora Court, Mail Stop F703 Aurora CO 80011 U.S.A"},{"name":"Department of Pathology; University of Colorado Denver; Anschutz Medical Campus, 1665 Aurora Court, Mail Stop F703 Aurora CO 80011 U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,7,8]]},"reference":[{"key":"10.1111\/bjd.12279-BIB0001|bjd12279-cit-0001","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12279-BIB0002|bjd12279-cit-0002","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12279-BIB0003|bjd12279-cit-0003","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12279-BIB0004|bjd12279-cit-0004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00403-012-1223-7","article-title":"Upcoming strategies for the treatment of metastatic melanoma","volume":"304","author":"Spagnolo","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/bjd.12279-BIB0005|bjd12279-cit-0005","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1111\/bjd.12279-BIB0006|bjd12279-cit-0006","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12279-BIB0007|bjd12279-cit-0007","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12279-BIB0008|bjd12279-cit-0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12279-BIB0009|bjd12279-cit-0009","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12279-BIB0010|bjd12279-cit-0010","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archderm.144.6.779","article-title":"Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib","volume":"144","author":"Hong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12279-BIB0011|bjd12279-cit-0011","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","article-title":"Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway","volume":"148","author":"Huang","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12279-BIB0012|bjd12279-cit-0012","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2012.06.045","article-title":"Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma","volume":"67","author":"Boyd","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12279-BIB0013|bjd12279-cit-0013","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886)","volume":"29","author":"Balagula","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1111\/bjd.12279-BIB0014|bjd12279-cit-0014","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-09-1766","article-title":"Mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders","volume":"16","author":"Schad","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1111\/bjd.12279-BIB0015|bjd12279-cit-0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12279-BIB0016|bjd12279-cit-0016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1111\/bjd.12279-BIB0017|bjd12279-cit-0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"key":"10.1111\/bjd.12279-BIB0018|bjd12279-cit-0018","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2010.09989.x","article-title":"Activating BRAF mutations in eruptive melanocytic naevi","volume":"163","author":"Sekulic","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12279-BIB0019|bjd12279-cit-0019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.jid.5700490","article-title":"Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations","volume":"127","author":"Bauer","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.12279-BIB0020|bjd12279-cit-0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/DAD.0b013e31816a8c6d","article-title":"Granulomatous inflammation in nevi undergoing regression (halo phenomenon): a report of six cases","volume":"30","author":"Denianke","year":"2008","journal-title":"Am J Dermatopathol"},{"key":"10.1111\/bjd.12279-BIB0021|bjd12279-cit-0021","first-page":"9527","article-title":"RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 2010; 70:5518-27","volume":"70","author":"Yang","year":"2010","journal-title":"Erratum in: Cancer Res"},{"key":"10.1111\/bjd.12279-BIB0022|bjd12279-cit-0022","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"28","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1111\/bjd.12279-BIB0023|bjd12279-cit-0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/1523-1747.ep12274521","article-title":"Analysis of major histocompatibility antigens and the mononuclear cell infiltrate in halo nevi","volume":"85","author":"Bergman","year":"1985","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.12279-BIB0024|bjd12279-cit-0024","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0560.1994.tb00704.x","article-title":"Characterization of the mononuclear infiltrate involved in regression of halo nevi","volume":"21","author":"Akasu","year":"1994","journal-title":"J Cutan Pathol"},{"key":"10.1111\/bjd.12279-BIB0025|bjd12279-cit-0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2133.1973.tb07517.x","article-title":"Immunological associations of the halo nevus with cutaneous malignant melanoma","volume":"88","author":"Copeman","year":"1973","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12279-BIB0026|bjd12279-cit-0026","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12279-BIB0027|bjd12279-cit-0027","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archderm.141.7.865","article-title":"Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature","volume":"141","author":"Hurst","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12279-BIB0028|bjd12279-cit-0028","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/CJI.0b013e3181eef779","article-title":"Sarcoidosis induced by interferon-\u03b1 in melanoma patients: incidence, clinical manifestations, and management strategies","volume":"33","author":"Heinzerling","year":"2010","journal-title":"J Immunother"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12279\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:04:25Z","timestamp":1676383465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/169\/1\/172\/6615167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12279","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}